insitro to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Leaders to Participate in Multiple Industry Forums Throughout Healthcare Week

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI therapeutics company built on causal biology, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company update, including its AI-enabled discovery engine and therapeutic candidates advancing to the clinic, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 12, at 4:00 p.m. PT in San Francisco.

Additional insitro participation at healthcare week events:

• Longwood Healthcare Leaders’ San Francisco CEO Conference
  Daphne Koller, Ph.D., will participate on the panel "Identifying Next-Generation Therapeutics" on Sunday, Jan. 11, at 1:30 p.m. PT
  
• KPMG + Goodwin Symposium
  Mary Rozenman, Ph.D., CFO and CBO, will join the panel "Transaction to Transformation: Innovative End-to-End Strategies for Life Sciences Companies Amid Market Volatility" on Wednesday, Jan. 14, at 11:30 a.m. PT.

insitro's J.P. Morgan presentation will be made available on the insitro website following the event.

About insitro

insitro is the AI therapeutics company built on causal biology. By generating an integrated, multimodal corpus of human and cellular data and analyzing it with machine learning, insitro’s platform aims to reveal how disease begins, progresses, and can be resolved. The company applies this approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience. insitro is backed by world-class investors and has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships.